Barbara A. de Weijer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Barbara A. de Weijer has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
A. van de Laar
Department of Surgery; Slotervaart Hospital; Amsterdam The Netherlands
1 shared publication- Arnold W. J. M. van de Laar
Department of surgery, MC Slotervaart, Amsterdam, the Netherlands
1 shared publication Arnold van de Laar
Slotervaart Hospital
1 shared publication- Breg Braak
Department of Gastroenterology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
1 shared publication E. Aarts
Departments of Surgery and Internal Medicine; Rijnstate Hospital; Arnhem The Netherlands
1 shared publicationE. Fliers
Department of Endocrinology and Metabolism; Academic Medical Center; University of Amsterdam; Amsterdam the Netherlands
1 shared publication
Latest Publications
Hepatic and peripheral insulin sensitivity do not improve 2 weeks after bariatric surgery
Objective Bariatric surgery has rapid metabolic effects on glucose metabolism before the occurrence of clinically significant weight loss. This suggests an acute effect of the surgery itself, e.g., resulting from bypassing the nutrient flow from the proximal gastrointestinal tract. Rapid effects of Roux‐en‐Y gastric bypass surgery (RYGB) on glucose metabolism were defined. Design and Methods Glucose metabolism and total triglyceride hydrolysis in the basal state and during a hyperinsulinemic euglycemic clamp using stable isotopes 2 weeks were studied before and after RYGB. Results Eighteen pre‐menopausal women scheduled for RYGB were included. 2 weeks after RYGB median weight loss was 7.8 kg. Basal insulin and glucose levels decreased after surgery. Endogenous glucose production (EGP) was lower after surgery. In addition, insulin levels were lower during the clamp after surgery, suggesting enhanced clearance. Hepatic and peripheral insulin sensitivity did not change. Free fatty acid (FFA) levels increased after surgery both in the basal state and during the first step of the clamp. Total triglyceride hydrolysis did not change in the basal state and tended to be higher during hyperinsulinemia. Conclusions Within 2 weeks, RYGB reduces basal EGP as well as insulin and glucose levels without an acute beneficial effect on hepatic or peripheral insulin sensitivity. The latter may be explained by higher rates of lipolysis and exposure to FFA induced by the hypocaloric state.
Hepatic and peripheral insulin sensitivity do not improve 2 weeks after bariatric surgery
Objective Bariatric surgery has rapid metabolic effects on glucose metabolism before the occurrence of clinically significant weight loss. This suggests an acute effect of the surgery itself, e.g., resulting from bypassing the nutrient flow from the proximal gastrointestinal tract. Rapid effects of Roux‐en‐Y gastric bypass surgery (RYGB) on glucose metabolism were defined. Design and Methods Glucose metabolism and total triglyceride hydrolysis in the basal state and during a hyperinsulinemic euglycemic clamp using stable isotopes 2 weeks were studied before and after RYGB. Results Eighteen pre‐menopausal women scheduled for RYGB were included. 2 weeks after RYGB median weight loss was 7.8 kg. Basal insulin and glucose levels decreased after surgery. Endogenous glucose production (EGP) was lower after surgery. In addition, insulin levels were lower during the clamp after surgery, suggesting enhanced clearance. Hepatic and peripheral insulin sensitivity did not change. Free fatty acid (FFA) levels increased after surgery both in the basal state and during the first step of the clamp. Total triglyceride hydrolysis did not change in the basal state and tended to be higher during hyperinsulinemia. Conclusions Within 2 weeks, RYGB reduces basal EGP as well as insulin and glucose levels without an acute beneficial effect on hepatic or peripheral insulin sensitivity. The latter may be explained by higher rates of lipolysis and exposure to FFA induced by the hypocaloric state.
- Open Access
- 1 January 2011
- Published by Springer Nature in EJNMMI Research
- Vol. 1 (1) , 37
Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects
Obesity is a result of a relative excess in energy intake over energy expenditure. These processes are controlled by genetic, environmental, psychological and biological factors. One of the factors involved in the regulation of food intake and satiety is dopaminergic signalling. A small number of studies have reported that striatal dopamine D2/D3 receptor [D2/3R] availability is lower in morbidly obese subjects. To confirm the role of D2/3R in obesity, we measured striatal D2/3R availability, using [123I]IBZM SPECT, in 15 obese women and 15 non-obese controls. Striatal D2/3R availability was 23% (p = 0.028) lower in obese compared with non-obese women. This study is an independent replication of the finding that severely obese subjects have lower striatal D2/3R availability. Our findings invigorate the evidence for lower striatal D2/3R availability in obesity and confirm the role of the striatal dopaminergic reward system in obesity.
- 1 January 2011
- Published by Springer Nature in EJNMMI Research
- Vol. 1 (1) , 37
Open AccessLower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects
Obesity is a result of a relative excess in energy intake over energy expenditure. These processes are controlled by genetic, environmental, psychological and biological factors. One of the factors involved in the regulation of food intake and satiety is dopaminergic signalling. A small number of studies have reported that striatal dopamine D2/D3 receptor [D2/3R] availability is lower in morbidly obese subjects. To confirm the role of D2/3R in obesity, we measured striatal D2/3R availability, using [123I]IBZM SPECT, in 15 obese women and 15 non-obese controls. Striatal D2/3R availability was 23% (p = 0.028) lower in obese compared with non-obese women. This study is an independent replication of the finding that severely obese subjects have lower striatal D2/3R availability. Our findings invigorate the evidence for lower striatal D2/3R availability in obesity and confirm the role of the striatal dopaminergic reward system in obesity.